Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Phathom Pharmaceuticals, Inc. (PHAT : NSDQ)

• Company Description    Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's product pipeline consists of vonoprazan, which are in clinical stage. Phathom Pharmaceuticals Inc. is based in Buffalo Grove, United States. Number of Employees: 427

• Price / Volume Information    Yesterday's Closing Price: $11.84 Daily Weekly Monthly 20 Day Moving Average: 1,077,921 shares Shares Outstanding: 70.94 (millions) Market Capitalization: $839.98 (millions) Beta: 0.44 52 Week High: $19.71 52 Week Low: $2.21 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.08% 11.10% 12 Week 8.62% -1.33% Year To Date 45.81% 32.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 100 CAMPUS DRIVE SUITE 102 - FLORHAM PARK,NJ 07932 USA ph: 877-742-8466 fax: - ir@phathompharma.com http://www.phathompharma.com

• General Corporate Information    Officers Terrie Curran - President; Chief Executive Officer and Director Molly Henderson - Chief Financial and Business Officer Michael F. Cola - Director Frank Karbe - Director Heidi Kunz - Director Peer Information Phathom Pharmaceuticals, Inc. (CORR.) Phathom Pharmaceuticals, Inc. (RSPI) Phathom Pharmaceuticals, Inc. (CGXP) Phathom Pharmaceuticals, Inc. (BGEN) Phathom Pharmaceuticals, Inc. (GTBP) Phathom Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 71722W107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 70.94 Most Recent Split Date: (:1) Beta: 0.44 Market Capitalization: $839.98 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.42 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.77 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 7.37 EPS Growth vs. Year Ago Period: 33.33% vs. Previous Quarter: 21.74% Sales Growth vs. Year Ago Period: 439.36% vs. Previous Quarter: 38.51% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - -90.40 03/31/25 - -90.11 12/31/24 - -86.28 Current Ratio 06/30/25 - 2.38 03/31/25 - 3.58 12/31/24 - 4.20 Quick Ratio 06/30/25 - 2.35 03/31/25 - 3.54 12/31/24 - 4.16 Operating Margin 06/30/25 - -259.59 03/31/25 - -379.49 12/31/24 - -562.67 Net Margin 06/30/25 - -289.51 03/31/25 - -422.42 12/31/24 - -605.09 Pre-Tax Margin 06/30/25 - -289.51 03/31/25 - -422.42 12/31/24 - -605.09 Book Value 06/30/25 - -5.81 03/31/25 - -4.85 12/31/24 - -3.71 Inventory Turnover 06/30/25 - 4.62 03/31/25 - 3.87 12/31/24 - 3.20 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©